U
ULTI
vs
O
Oslo OBX
Over the past 12 months, ULTI has underperformed Oslo OBX, delivering a return of -29% compared to the Oslo OBX's +17% growth.
Stocks Performance
ULTI vs Oslo OBX
Performance Gap
ULTI vs Oslo OBX
Performance By Year
ULTI vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ultimovacs ASA
Glance View
Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The firm is performing a broad clinical development program with clinical trials in Europe and the USA.